Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.
Christopher J SweeneyRussell PetryChang XuMerrida ChildressJie HeDavid FabrizioOle V GjoerupSamantha MorleyTimothy CatlettZoe June AssafKobe YuenMatthew J WongchenkoKalpit ShahPratyush GuptaPriti S HegdeLincoln W PasquinaSanjeev MariathasanRyon P GrafThomas PowlesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
In a large cohort of mCRPC patients receiving enzalutamide after abiraterone, we demonstrate the utility of a new tissue-agnostic assay for monitoring molecular response based on ctDNA TF detection and dynamics. CtDNA TF provides a minimally-invasive, complementary biomarker to PSA testing and may refine personalized treatment approaches.